BPC-157 Dosage: Why There Is No Established Dose and How Prescribers Frame the Decision

BPC-157 dosage is one of the most searched questions about the peptide, and the most honest answer is also the least satisfying: there is no established human dose. BPC-157 is not an FDA-approved drug, it has never been through dose-finding trials of the kind that set a labeled dose, and in its July 2026 review the FDA specifically noted that dose-response relationships have not been established. Numbers circulating online come from animal studies scaled by assumption, from vendor marketing, or from individual practice habits — not from controlled human data.

This guide explains why that gap exists, what a prescriber actually decides when BPC-157 is used, and what the regulatory position means for anyone planning a protocol.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Why There Is No Established BPC-157 Dose

A labeled dose normally comes from a specific sequence of studies: pharmacokinetics in humans, dose-ranging trials that compare several doses against placebo, and larger trials confirming the chosen dose. BPC-157 has had none of these at scale.

The preclinical literature is large, but animal doses do not translate directly to people. Scaling a rodent dose to a human involves assumptions about metabolism and body surface area, and for a peptide whose human pharmacokinetics are poorly characterized, those assumptions are weak.

For the full evidence picture, see our BPC-157 clinical research review, and for the compound itself, the BPC-157 library page.

What a Prescriber Actually Decides

Without a labeled dose, a BPC-157 protocol is a set of prescriber judgments. These are the variables that shape it.

Route of Administration

BPC-157 has been marketed in injectable, oral, nasal, and topical forms. The route follows the rationale:

• Subcutaneous injection is the form most often discussed for musculoskeletal and soft-tissue indications.
• Oral forms are discussed for gastrointestinal indications, reflecting the peptide's gastric origin and the GI emphasis of its preclinical research. BPC-157 is described as unusually stable in gastric conditions compared with many peptides, though human oral bioavailability data are limited.
• Topical and nasal forms exist but have the least supporting data.

Duration and Reassessment

Protocols are generally time-limited — a defined course with reassessment — rather than open-ended. Duration is tied to the indication and the patient's response, and a clear stopping point is part of responsible prescribing for a compound with no long-term human safety data.

The Specific Preparation

Dose amounts only mean something against a specific compounded preparation: its concentration, its salt form (FDA reviewed both BPC-157 free base and BPC-157 acetate), and its volume. That is why dosing is set with the compounding pharmacy's formulation in hand. For reconstitution arithmetic — concentration, draw volume, and syringe units — use our peptide calculator.

Patient Selection

Because BPC-157 is studied for promoting new blood-vessel formation, patients with active or recent malignancy warrant particular caution. Pregnancy, breastfeeding, and competitive athletes subject to anti-doping rules are also exclusions or significant cautions. See BPC-157 side effects.

A Note on Numbers You Will See Online

Specific microgram figures for BPC-157 are widely repeated online. We do not reproduce them here, for three reasons:

1. They are not derived from human dose-finding trials. Most trace back to animal studies or to practice convention.
2. The FDA looked for this data and did not find it. Its July 2026 briefing found dose-response relationships not established.
3. Product quality varies. FDA described BPC-157 as not well-characterized, and research-chemical products may not contain what their labels state — which makes any number unreliable without a verified preparation.

A dose is a prescriber's decision for an individual patient — and for BPC-157 it presupposes a lawful source, which FDA's July 2026 proposal puts in serious doubt.

BPC-157 Combined With Other Peptides

BPC-157 is frequently combined with TB-500, a pairing informally called the wolverine stack. Our TB-500 dosage and half-life reference describes the loading, maintenance, and cycling frameworks used in those protocols. Combining peptides does not create a better-evidenced dose for either; it adds a second set of uncertainties.

For surgical recovery specifically — including the timing questions around angiogenesis — see BPC-157 for post-surgical recovery.

Regulatory Status Matters More Than the Dose

In 2026, the practical question for most practices is not how much BPC-157 to prescribe but whether it can be lawfully compounded at all. FDA's briefing documents for the July 23, 2026 PCAC meeting proposed not adding BPC-157 (free base or acetate) to the 503A Bulks List, citing characterization gaps, insufficient effectiveness evidence, and insufficient human safety data. See BPC-157 and the FDA 503A decision and is BPC-157 legal in 2026.

Our FDA peptide status tracker also records a separate Category 1 nomination under the name pentadecapeptide. That is the same substance, and the safety concerns behind the Category 2 placement apply equally. Check the tracker for current status and confirm availability with the compounding partner before planning any protocol.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the BPC-157 dosage?

There is no established human dose. BPC-157 is not FDA-approved, has not been through human dose-finding trials, and FDA's 2026 review found dose-response relationships not established. Dosing is prescriber-determined against a specific compounded preparation.

Why won't you list a BPC-157 dose in mcg?

Figures circulating online are not derived from human trials — most trace to animal studies or practice convention. We don't present numbers that the evidence doesn't support.

Is oral or injectable BPC-157 better?

It depends on the rationale. Injection is most often discussed for musculoskeletal injury; oral forms for gastrointestinal indications, reflecting the peptide's gastric origin. Human bioavailability data for either route are limited.

How long is a BPC-157 course?

Protocols are generally time-limited with reassessment rather than open-ended. Duration depends on the indication and response and is set by the prescriber.

Can BPC-157 still be prescribed in 2026?

It was never FDA-approved. In July 2026 FDA proposed not adding it to the 503A Bulks List, which places compounded access in serious doubt. Check the FDA tracker and confirm with the compounding partner.